Literature DB >> 8254742

v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.

R Hrdlicková1, J Nehyba, E H Humphries.   

Abstract

The c-rel gene is a member of NF-kappa B/rel family of transcription factors that regulate expression of a variety of immunoregulatory molecules. The viral oncogene, v-rel, is a truncated and mutated form of the turkey c-rel gene expressed by reticuloendotheliosis virus, strain T. In this study, we demonstrated that three avian immunoregulatory receptors, major histocompatibility (MHC) antigens class I and class II as well as the interleukin-2 receptor (IL-2R), were induced on the surface of splenic tumor cells isolated from chickens infected with reticuloendotheliosis virus, strain T. All cell lines derived from splenic tumors expressed these three proteins. Their expression also correlated with the appearance of endogenous c-rel during a graft-versus-host reaction. In vitro, both c-rel and v-rel induced MHC class I, MHC class II, and IL-2R on an avian B-lymphoid cell line, DT95, and a T-lymphoid cell line, MSB-1. Quantitative kinetic analysis demonstrated both the accumulation of MHC class II mRNA and the appearance of surface MHC class II protein in response to the synthesis of either v-rel or c-rel. We show that v-rel induced the expression of MHC class II in the avian B-cell lines DT40 and DT95 more rapidly than c-rel and that, several weeks after infection, v-rel induced MHC class II as much as 50-fold more efficiently than c-rel. Finally, in vitro infection of splenocytes with retroviruses that express v-rel or c-rel induced MHC class I, MHC class II, and IL-2R expression. Quantitative analysis confirmed that p59v-rel was consistently more efficient at inducing expression of all three immunoregulatory receptors than exogenous p68c-rel. These data suggest that during tumor development, v-rel functions to induce (or suppress) the expression of genes similarly induced (or suppressed) by c-rel. The observations reported in this study are not in agreement with a model in which v-rel promotes tumor development by functioning as a dominant negative mutant of c-rel. In contrast, these findings support the hypothesis that lymphocyte immortalization and tumor development are the result, at least in part, of the capacity of v-rel to function as a dominant positive mutant that induces expression of genes normally regulated by c-rel.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254742      PMCID: PMC236290     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

Review 1.  The Rel family: models for transcriptional regulation and oncogenic transformation.

Authors:  H R Bose
Journal:  Biochim Biophys Acta       Date:  1992-09-14

2.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  The transforming protein of avian reticuloendotheliosis virus is a soluble cytoplasmic protein which is associated with a protein kinase activity.

Authors:  D S Walro; N K Herzog; J Zhang; M Y Lim; H R Bose
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

4.  Quantitative immunocytochemical assay for infectious avian retroviruses.

Authors:  A W Stoker; M J Bissell
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

5.  The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65.

Authors:  P Ghosh; T H Tan; N R Rice; A Sica; H A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

6.  Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning.

Authors:  I S Chen; T W Mak; J J O'Rear; H M Temin
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

7.  Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

Authors:  I Kitajima; T Shinohara; J Bilakovics; D A Brown; X Xu; M Nerenberg
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

8.  Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel.

Authors:  T H Tan; G P Huang; A Sica; P Ghosh; H A Young; D L Longo; N R Rice
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

9.  Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization.

Authors:  M Meyer; W H Caselmann; V Schlüter; R Schreck; P H Hofschneider; P A Baeuerle
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

10.  Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression.

Authors:  G Boehmelt; A Walker; N Kabrun; G Mellitzer; H Beug; M Zenke; P J Enrietto
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  25 in total

1.  A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.

Authors:  Jirí Nehyba; Radmila Hrdlicková; Joan Burnside; Henry R Bose
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

4.  Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.

Authors:  D W White; G A Pitoc; T D Gilmore
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

5.  AP-1 factors play an important role in transformation induced by the v-rel oncogene.

Authors:  J Kralova; A S Liss; W Bargmann; H R Bose
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

6.  Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.

Authors:  Jarmila Kralova; Andrew S Liss; William Bargmann; Cullen Pendleton; Janani Varadarajan; Emin Ulug; Henry R Bose
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.

Authors:  M You; P T Ku; R Hrdlicková; H R Bose
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

8.  Constitutive and inducible kappa B binding activities in the cytosol of v-Rel-transformed lymphoid cells.

Authors:  J Hodgson; P J Enrietto
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms.

Authors:  E M Rottjakob; S Sachdev; C A Leanna; T A McKinsey; M Hannink
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

10.  Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor.

Authors:  S Gerondakis; A Strasser; D Metcalf; G Grigoriadis; J Y Scheerlinck; R J Grumont
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.